Working with TipRanks
Follow Us
Stocks
ETFs
Options
Commodities
Crypto
Currency
Pro Newsletters
Research Tools
Calendars
Economic Indicators
Calculators
Education
About Us
Working with TipRanks
Follow Us
Gossamer Bio Inc (GOSS)
NASDAQ:GOSS
Holding GOSS?
Track your performance easily
GOSS Stock Chart & Stats
Day’s Range$0 - $0
52-Week Range$0.45 - $1.60
Previous Close$0.91
Volume566.08K
Average Volume (3M)1.69M
Market Cap
$217.18M
Enterprise Value-$148.37M
Total Cash (Recent Filing)$354.49M
Total Debt (Recent Filing)$0.00
Price to Earnings (P/E)―
Beta2.55
Next Earnings
Nov 12, 2024EPS Estimate
-$0.15Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.40
Shares Outstanding226,227,259
10 Day Avg. Volume855,435
30 Day Avg. Volume1,689,423
Standard Deviation0.24
R-Squared0.17
Alpha-0.04
Financial Highlights & Ratios
Price to Book (P/B)7.59
Price to Sales (P/S)N/A
Price to Cash Flow (P/CF)-1.00
P/FCF Ratio0.00
Enterprise Value/Market CapN/A
Enterprise Value/Revenue-1.55
Enterprise Value/Gross Profit-10.00T>
Enterprise Value/Ebitda2.40
Forecast
1Y Price Target
$7.50Price Target Upside681.25% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering7
Gossamer Bio News
Bulls Say, Bears Say
Bulls Say
Clinical DataSeralutinib led to further reductions in pulmonary vascular resistance (PVR), suggesting durable persistence of treatment effect.
CollaborationsThe collaboration with Chiesi supports confidence in seralutinib's potential by advancing the seralutinib program to a Phase 3 registrational study.
Financial HealthGOSS' cash runway extension with the addition of $160M in development reimbursement payment.
Bears Say
Clinical Trial EnrollmentSome investors remain cautious about GOSS' ability to enroll their target PAH patient population in light of Winrevair's approval in the US.
Clinical TrialsNeither an improvement in PVR nor in the 6-minute walk test (6MWT) was seen with treatment with AV-101 vs. placebo, which resulted in missing both the primary and secondary endpoints of the trial.
Market CompetitionSkeptical that acceleration of that path forward (even if it is the more attractive of the potential pivotal studies) is enough to overcome the backdrop of poor optics given what is expected to be a compelling Winrevair launch and limited GOSS catalyst flow over the next 12 months.
---
Ownership Overview
11.56% Insiders
13.00% Mutual Funds
56.92% Other Institutional Investors
18.52% Public Companies and Individual Investors
Risk Analysis
Main Risk Category
Tech & InnovationRisks related to the company’s reliance on technology and ability to make innovative products
Website Traffic
Sorry, No Data AvailableThere is no website visitor data available for this stock.
---
GOSS FAQ
What was Gossamer Bio Inc’s price range in the past 12 months?
Gossamer Bio Inc lowest stock price was $0.45 and its highest was $1.60 in the past 12 months.
What is Gossamer Bio Inc’s market cap?
Currently, no data Available
When is Gossamer Bio Inc’s upcoming earnings report date?
Gossamer Bio Inc’s upcoming earnings report date is Nov 12, 2024 which is in 53 days.
How were Gossamer Bio Inc’s earnings last quarter?
Gossamer Bio Inc released its earnings results on Aug 12, 2024. The company reported $0.22 earnings per share for the quarter, missing the consensus estimate of $0.507 by -$0.287.
Is Gossamer Bio Inc overvalued?
According to Wall Street analysts Gossamer Bio Inc’s price is currently Undervalued.
Does Gossamer Bio Inc pay dividends?
Gossamer Bio Inc does not currently pay dividends.
What is Gossamer Bio Inc’s EPS estimate?
Gossamer Bio Inc’s EPS estimate is -$0.15.
How many shares outstanding does Gossamer Bio Inc have?
Gossamer Bio Inc has 226,227,260 shares outstanding.
What happened to Gossamer Bio Inc’s price movement after its last earnings report?
Gossamer Bio Inc reported an EPS of $0.22 in its last earnings report, missing expectations of $0.507. Following the earnings report the stock price went up 2.5%.
Which hedge fund is a major shareholder of Gossamer Bio Inc?
Among the largest hedge funds holding Gossamer Bio Inc’s share is Platinum Investment Management. It holds Gossamer Bio Inc’s shares valued at 3M.
---
Gossamer Bio Stock Smart Score
Unlock Smart Score
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$7.50 (681.25% Upside)
$7.50 (681.25% Upside)
Blogger Sentiment
Bullish
GOSS Sentiment 100%
Sector Average 70%
Sector Average 70%
Hedge Fund Trend
Decreased
By 8.1M Shares
Last Quarter.
Last Quarter.
Insider Transactions
Bought Shares
Worth $322.0K over
the Last 3 Months
the Last 3 Months
Crowd Wisdom
Very Positive
Last 7 Days ▲ 3.5%
Last 30 Days ▲ 2.5%
Last 30 Days ▲ 2.5%
News Sentiment
Very Bullish
Bullish news 100%
Bearish news 0%
Bearish news 0%
Technicals
SMA
Negative
20 days / 200 days
Momentum
-3.39%
12-Months-Change
Fundamentals
Return on Equity
-863.39%
Trailing 12-Months
Asset Growth
105.48%
Trailing 12-Months
Company Description
Gossamer Bio Inc
Gossamer Bio, Inc. engages in discovering, acquiring, developing, and commercializing therapeutics in the disease areas of immunology, inflammation, and oncology. Its primary product candidate is GB001, which is intended for the treatment of moderate-to-severe eosinophilic asthma and other allergic conditions. The company was founded by Faheem Hasnain and Sheila Gujrathi in 2015 and is headquartered in San Diego, CA.
---
GOSS Stock 12 Month Forecast
Average Price Target
$7.50
▲(681.25% Upside)
Technical Analysis
Best Analysts Covering GOSS
1 Year
1 Year Success Rate
5/11 ratings generated profit
1 Year Average Return
-23.79%
reiterated a buy rating 4 days ago
Copying Andreas Argyrides's trades and holding each position for 1 Year would result in 45.45% of your transactions generating a profit, with an average return of -23.79% per trade.
---